secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2026-01-21T23:59:59+00:00
Accession:  0001837607-26-000005
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 3.02, 5.02, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON shareholders approve PIPE/Daewoong exchange; BPD Type 2a meeting held with FDA
--------------------------------------------------------------------------------

- Shareholders approved PIPE financing, Daewoong note exchange, and 2023 incentive plan at special meeting; exchange closed Jan 21.
- Daewoong exchanged $15M senior secured notes for 11.9M shares, 11.2M pre-funded warrants, $1.5M new note, and 8M warrants.
- Second closing of PIPE expected week of Jan 26: 4.6M shares, 6.6M warrants, and up to 6.6M true-up warrants.
- AEON held BPD Type 2a meeting with FDA for ABP-450 biosimilar; awaiting official minutes within ~30 days.
- Fifth amendment to license agreement with Daewoong adjusts termination purchase right based on Daewoong's sale of 50% of its shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000005/0001837607-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760726000005/aeon-20260121x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer